Uploaded June 2026 | Updated September 2026, 2 weeks ago
GSK has announced its largest acquisition in more than a decade, paying $10.6 billion for US biotech company NewValence and its promising lung cancer treatments.
In this video, Julian Hoffman joins Dan Jones to examine what GSK is buying, why the company is making such a significant push into oncology, and how the deal fits into its long-term strategy. We also discuss the looming patent cliff facing GSK's HIV franchise, why management believes cancer drugs can help fill that revenue gap, and whether investors should be concerned about the price paid.
#investing #finance #personalfinance #investments #business #GSK #Pharmaceuticals #Biotech #HealthcareStocks #Investing #StockMarket #CancerTreatment #Oncology #UKStocks #InvestorsChronicle #Pharma #LungCancer #HealthcareInvesting
Listen to our podcasts: investorschronicle.co.uk/podcasts/?utm_medium=social&utm_source=youtube&utm_campaign=editorial
Subscribe to Investors' Chronicle: investorschronicle.co.uk/product-matrix?utm_medium=social&utm_source=youtube&utm_campaign=editorial
Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. Our award-winning expert writers research hundreds of companies and funds suitable for all risk appetites, to provide clear, independent recommendations for individual investors who want to make their money grow and outline how to make the most of different types of investment vehicles at all stages of your life.
Follow The Companies and Markets Show on @YouTube: youtube.com/playlist?list=PLnrcXTQl38frCLdb4HDxepjhvod-gN662
Follow Lee and the IC: youtube.com/playlist?list=PLnrcXTQl38fqB-A5bJJ-GtFjm3Q9S9Xnx
Listen to our interviews here: youtube.com/playlist?list=PLnrcXTQl38fo1Oio19rTsLt9fD2s4hKst
Follow us on LinkedIn: linkedin.com/showcase/financial-times---investors-chronicle
Follow us on Instagram: instagram.com/investorschronicle/?hl=en
Get the latest investing updates on WhatsApp: whatsapp.com/channel/0029VaD6zjW9WtBxc0gFG13F
GSK has announced its largest acquisition in more than a decade, paying $10.6 billion for US biotech company NewValence and its promising lung cancer treatments.
In this video, Julian Hoffman joins Dan Jones to examine what GSK is buying, why the company is making such a significant push into oncology, and how the deal fits into its long-term strategy. We also discuss the looming patent cliff facing GSK's HIV franchise, why management believes cancer drugs can help fill that revenue gap, and whether investors should be concerned about the price paid.
#investing #finance #personalfinance #investments #business #GSK #Pharmaceuticals #Biotech #HealthcareStocks #Investing #StockMarket #CancerTreatment #Oncology #UKStocks #InvestorsChronicle #Pharma #LungCancer #HealthcareInvesting
Listen to our podcasts: investorschronicle.co.uk/podcasts/?utm_medium=social&utm_source=youtube&utm_campaign=editorial
Subscribe to Investors' Chronicle: investorschronicle.co.uk/product-matrix?utm_medium=social&utm_source=youtube&utm_campaign=editorial
Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. Our award-winning expert writers research hundreds of companies and funds suitable for all risk appetites, to provide clear, independent recommendations for individual investors who want to make their money grow and outline how to make the most of different types of investment vehicles at all stages of your life.
Follow The Companies and Markets Show on @YouTube: youtube.com/playlist?list=PLnrcXTQl38frCLdb4HDxepjhvod-gN662
Follow Lee and the IC: youtube.com/playlist?list=PLnrcXTQl38fqB-A5bJJ-GtFjm3Q9S9Xnx
Listen to our interviews here: youtube.com/playlist?list=PLnrcXTQl38fo1Oio19rTsLt9fD2s4hKst
Follow us on LinkedIn: linkedin.com/showcase/financial-times---investors-chronicle
Follow us on Instagram: instagram.com/investorschronicle/?hl=en
Get the latest investing updates on WhatsApp: whatsapp.com/channel/0029VaD6zjW9WtBxc0gFG13F
